V590, a SARS-CoV-2 vaccine developed in partnership with IAVI that uses the same recombinant vesicular stomatitis virus (rVSV) vaccine platform used to develop the company’s approved Ebola vaccine, Ervebo, will begin clinical trials this year. (Also see "Merck’s Ervebo Becomes World’s First Approved Ebola Vaccine " - Scrip, 12 November, 2019.)

V591, a SARS-CoV-2 vaccine developed with a measles virus vector platform developed at the Institut Pasteur and licensed exclusively to Themis, will move into the clinic in the third quarter of this year. (Also see "Wary Of Coronavirus Hype And Haste, Themis Looks To Future As Part Of Merck & Co." - Scrip, 17 June, 2020.)

MK-4482 (EIDD-2801), an orally available nucleoside analog that disrupts replication of the SARS-CoV-2 viral genome in development with partner Ridgeback, is being tested now in three Phase II studies.

Merck Outlines COVID-19 Vaccine And Antiviral Plans As Pandemic Dents Q2 Sales

More from Earnings

More from Business